ESSA PHARMA INC's ticker is EPIX and the CUSIP is 29668H708. A total of 61 filers reported holding ESSA PHARMA INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37,080 | +162.8% | 12,000 | +129.7% | 0.00% | – |
| Q2 2023 | $14,107 | -9.1% | 5,225 | 0.0% | 0.00% | – |
| Q1 2023 | $15,518 | +19.4% | 5,225 | 0.0% | 0.00% | – |
| Q4 2022 | $13,000 | +62.5% | 5,225 | +23.7% | 0.00% | – |
| Q3 2022 | $8,000 | -38.5% | 4,225 | 0.0% | 0.00% | – |
| Q2 2022 | $13,000 | -50.0% | 4,225 | 0.0% | 0.00% | – |
| Q1 2022 | $26,000 | -60.0% | 4,225 | -7.3% | 0.00% | – |
| Q4 2021 | $65,000 | +27.5% | 4,559 | -28.8% | 0.00% | – |
| Q3 2021 | $51,000 | -92.3% | 6,401 | -72.4% | 0.00% | -100.0% |
| Q2 2021 | $662,000 | +3.8% | 23,165 | +5.6% | 0.00% | -50.0% |
| Q1 2021 | $638,000 | +282.0% | 21,945 | +56.8% | 0.00% | – |
| Q4 2020 | $167,000 | +153.0% | 14,000 | +47.4% | 0.00% | – |
| Q3 2020 | $66,000 | +11.9% | 9,500 | 0.0% | 0.00% | – |
| Q2 2020 | $59,000 | +73.5% | 9,500 | +11.8% | 0.00% | – |
| Q1 2020 | $34,000 | – | 8,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 8,748,629 | $15,923,000 | 0.66% |
| Soleus Capital Management, L.P. | 2,640,539 | $4,806,000 | 0.65% |
| Omega Fund Management, LLC | 328,196 | $597,000 | 0.22% |
| MPM BioImpact LLC | 405,700 | $738,000 | 0.18% |
| Bellevue Group AG | 5,898,583 | $10,736,000 | 0.15% |
| Rhenman & Partners Asset Management AB | 375,000 | $1,350,000 | 0.14% |
| PFM Health Sciences, LP | 1,478,252 | $2,690,000 | 0.10% |
| Frazier Life Sciences Management, L.P. | 692,910 | $1,261,000 | 0.10% |
| Avidity Partners Management LP | 2,460,000 | $4,477,000 | 0.09% |
| Eventide Asset Management | 1,561,251 | $2,841,000 | 0.06% |